- Market Capitalization, $K 113,643,648
- Shares Outstanding, K 2,541,795
- Annual Sales, $ 46,910 M
- Annual Income, $ 6,030 M
- 60-Month Beta 0.64
- Price/Sales 2.40
- Price/Cash Flow 15.34
- Price/Book 3.71
|Period||Period Low||Period High||Performance|
| || |
-2.05 (-4.44%)since 04/18/22
| || |
+1.11 (+2.58%)since 02/18/22
| || |
+4.59 (+11.60%)since 05/18/21
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.
Despite heightened market volatility, the healthcare industry is expected to grow significantly in 2022 amid surging chronic diseases worldwide, an aging population, increasing healthcare expenditure,...
The British drugmaker recently announced that it agreed to acquire a late-stage biopharmaceutical company.
Its late-stage pipeline is heavily weighted toward pandemic treatments.
With the latest federal interest rate hike and the possibility of further monetary policy tightening, market indices have been going haywire. Because volatility is expected to persist, with experts fearing...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline...
The cannabis industry has attracted significant investor attention over the past couple of years due to its growing use for both medical and recreational purposes. Also, the increasing legalization of...
Kuznicki Law PLLC is investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Sierra will...
Gilead (GILD) beats on earnings and revenues in the first quarter on strong Veklury sales. HIV business maintains momentum on Biktarvy.
The COVID-19 pandemic has given a boost to the pharmaceutical industry's revenues. And pharmaceutical companies are expected to remain in focus by investors as the demand for medicines rises with an increase...
|Glaxosmithkline Plc ADR|
|Vaneck Pharmaceutical ETF|
|Alps Hillman Active Value ETF|
|ETFMG Treatments Testing & Adv ETF|
|Avantis Responsible International Equity ETF|
|Value Line Dividend Idx ETF FT|
|3rd Resistance Point||45.45|
|2nd Resistance Point||45.18|
|1st Resistance Point||44.94|
|1st Support Level||44.44|
|2nd Support Level||44.17|
|3rd Support Level||43.93|